首页> 外文期刊>Journal of Cardiothoracic Surgery >Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion
【24h】

Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion

机译:聚维酮碘胸膜固定术与滑石粉胸膜固定术预防恶性胸腔积液复发

获取原文
           

摘要

Background Malignant pleural effusions continue to be a common problem in patients with metastatic disease, leading to a significant reduction in quality of life with progressive dyspnea, dry cough, chest pain and reduced physical activity. This study was conducted to compare the efficacy, safety, and outcome of Talc Powder Pleurodesis (TPP) with Povidone-iodine Pleurodesis (PIP) through a chest drain as a palliative preventive treatment of recurrent malignant pleural effusion. Methods A total of 39 neoplastic patients with recurrent malignant pleural effusion were enrolled in a prospective randomized trial. Twenty-one patients received Talc pleurodesis (group A), and eighteen patients (group B) received Povidone-iodine pleurodesis. The continuous variables were expressed as mean values?±?standard deviation (SD) and compared using the unpaired t-test. The discrete variables were expressed as percentage and compared using the chi-square test (χ2) test. p-values of less than 0.05 were considered significant. Results Our study included 11 males and 28 females, the mean age was (71.0?±?5.0) years for group A and (70.9?±?5.1) years for group B (non-significant). Post-procedure analgesic requirements were recorded in both groups. Four patients in each group had fever (>38°C) within 48 hours of the procedure. Both groups achieved good symptomatic relief. There were no in-hospital deaths. The mean post-procedure hospital stay was (4.7?±?1.2) days for group A and (4.2?±?1.0) for group B (non-significant). At follow-up recurrence of significant pleural effusion requiring intervention was noted in four and five patients in group A and group B, respectively (non-significant difference). Conclusion Povidone-iodine pleurodesis can be considered as a good alternative to Talc pleurodesis for recurrent malignant pleural effusion. The drug is available, cost effective, safe and can be administered through an intercostal drain and repeated if necessary.
机译:背景恶性胸腔积液仍然是转移性疾病患者的普遍问题,导致生活质量显着下降,并伴有进行性呼吸困难,干咳,胸痛和体力活动减少。这项研究的目的是比较滑石粉胸膜固定术(TPP)与聚维酮碘胸膜固定术(PIP)通过胸腔引流作为复发性恶性胸腔积液的姑息预防性治疗的疗效,安全性和结果。方法总共39例复发性恶性胸腔积液肿瘤患者被纳入一项前瞻性随机试验。 21例患者接受滑石粉胸膜固定术(A组),18例患者(B组)接受聚维酮碘碘胸膜固定术。连续变量表示为平均值±标准偏差(SD),并使用不成对的t检验进行比较。离散变量以百分比表示,并使用卡方检验(χ2)进行比较。小于0.05的p值被认为是重要的。结果我们的研究包括11位男性和28位女性,A组的平均年龄为(71.0±±5.0)岁,B组的平均年龄为(70.9±±5.1)岁(无统计学意义)。两组均记录了术后镇痛要求。每组四名患者在手术后48小时内发烧(> 38°C)。两组均取得了良好的症状缓解。没有院内死亡。 A组的平均术后住院天数为(4.7±±1.2)天,B组的平均术后住院时间为(4.2±±1.0)天(无统计学意义)。随访时,分别在A组和B组的4名和5名患者中发现需要进行干预的大量胸腔积液复发(无显着性差异)。结论聚维酮碘胸膜固定术可替代滑石粉胸膜固定术用于复发性恶性胸腔积液。该药物是可用的,具有成本效益的,安全的,可以通过肋间引流给药,并在必要时重复使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号